Zydus Cadila has received the tentative approval from the USFDA to market Deferasirox Tablets, 90 mg, 180 mg, and 360 mg (US RLD — Exjade Tablets). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
It is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non—transfusion—dependent thalassemia).
0 thoughts on “Zydus receives tentative approval from the USFDA for Deferasirox Tablets”